A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Completed · Phase 2 · Has a placebo group

Conditions studied: Hyperkalemia

In brief

The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels

Key facts

Study ID
NCT04780841
Run by
Ardelyx
People needed
109
Starts
2021-01-11
Expected to finish
2022-03-03
Last updated by the study team
2022-05-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.